Dashboard
Manage Tickers

INCYINCYTE CORP


$ 66.45 $ 1.95 (3.02 %)    

Monday, 16-Sep-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.16 $ 0.10 (0.02 %)
DIA $ 417.33 $ 0.38 (0.09 %)
SPY $ 562.87 $ 1.40 (0.25 %)
TLT $ 101.29 $ 0.66 (0.65 %)
GLD $ 238.61 $ 0.01 (0 %)
$ na
$ 64.50
$ 66.41 x 100
-- x --
$ 64.33 - $ 66.48
$ 50.27 - $ 70.36
2,021,372
na
12.24B
$ 0.53
$ 125.82
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

guggenheim-maintains-buy-on-incyte-raises-price-target-to-92
Guggenheim Maintains Buy on Incyte, Raises...
09/16/2024 16:45:26

Guggenheim analyst Michael Schmidt maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $86 to $92.

cantor-fitzgerald-reiterates-neutral-on-incyte
Cantor Fitzgerald Reiterates Neutral on In...
09/16/2024 12:29:32

Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:INCY) with a Neutral.

b-of-a-securities-maintains-neutral-on-incyte-raises-price-target-to-68
B of A Securities Maintains Neutral on Inc...
09/16/2024 12:19:53

B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $66 to...

reported-saturday-incyte-announced-results-from-phase-3-pod1um-303interaact2-trial-of-retifanlimab-zynyz-in-combination-with-platinum-based-chemotherapy-carboplatinpaclitaxel-for-inoperable-locally-recurrent-or-metastatic-squamous-cell-anal-carcinoma
Reported Saturday, Incyte Announced Result...
09/16/2024 09:23:30

Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secon...

reported-saturday-incyte-unveils-results-for-cdk2-inhibitor-incb123667-in-advanced-solid-tumors-ovarian-cancer-among-highlighted
Reported Saturday, Incyte Unveils Results ...
09/16/2024 07:58:52

New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event These results build u...

cantor-fitzgerald-reiterates-neutral-on-incyte
Cantor Fitzgerald Reiterates Neutral on In...
09/09/2024 17:09:02

Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:INCY) with a Neutral.

Core News & Articles
Eli Lilly And EVA Pharma Entered Into An A...
09/04/2024 10:06:33

Discovered By Incyte And Licensed To Lilly, Baricitinib Is For The Treatment Of Rheumatoid Arthritis, Alopecia Areata, Atopic D...

incyte-stock-a-deep-dive-into-analyst-perspectives-9-ratings
Incyte Stock: A Deep Dive Into Analyst Per...
09/03/2024 15:00:24

rbc-capital-reiterates-sector-perform-on-incyte-maintains-67-price-target
RBC Capital Reiterates Sector Perform on I...
09/03/2024 13:30:47

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $67 price target.

incyte-to-present-late-breaking-phase-3-results-for-retifanlimab-and-initial-data-from-phase-1-cdk2-inhibitor-program-at-the-esmo-congress-2024
Incyte To Present Late-Breaking Phase 3 Re...
08/21/2024 15:41:11

- Presidential Symposium to feature Phase 3 retifanlimab (Zynyz®) results in squamous cell anal carcinoma (SCAC); filing of sup...

incyte-seeks-expanded-fda-approval-for-lymphoma-drug-after-releasing-promising-topline-data-from-late-stage-study
Incyte Seeks Expanded FDA Approval For Lym...
08/16/2024 13:29:34

Incyte's Phase 3 inMIND trial of Monjuvi (tafasitamab) combined with lenalidomide and rituximab meets primary endpoints in ...

incyte-announces-topline-results-from-study-of-tafasitamab-met-its-primary-endpoint-of-progression-free-survival-in-relapsed-or-refractory-follicular-lymphoma-the-secondary-endpoint-of-pfs-results-by-blinded-independent-review-are-consistent-with-investigator-based-pfs-results-no-new-safety-signals-with-tafasitamab-were-observed
Incyte Announces Topline Results From Stud...
08/15/2024 20:34:33

- Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®) or placebo in combination with lenalidomide...

analyst-expectations-for-incytes-future
Analyst Expectations For Incyte's Future
08/15/2024 20:01:41

fda-approves-incytesyndax-partnered-drug-for-chronic-graft-versus-host-disease-a-post-transplant-complication
FDA Approves Incyte/Syndax Partnered Drug ...
08/15/2024 14:11:20

The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at...

rbc-capital-maintains-sector-perform-on-incyte-raises-price-target-to-67
RBC Capital Maintains Sector Perform on In...
08/15/2024 14:02:59

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $66...

Core News & Articles
Incyte, Syndax Secure FDA Approval For Nik...
08/14/2024 21:55:48

FDA has approved Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (G...

fda-approves-axatilimab-csfr-for-treatment-of-chronic-graft-versus-host-disease
FDA Approves Axatilimab-CSFR For Treatment...
08/14/2024 19:07:04

- Reuters 

deutsche-bank-maintains-hold-on-incyte-raises-price-target-to-60
Deutsche Bank Maintains Hold on Incyte, Ra...
08/01/2024 17:59:06

Deutsche Bank analyst James Shin maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $55 to $60.

citigroup-maintains-buy-on-incyte-raises-price-target-to-88
Citigroup Maintains Buy on Incyte, Raises ...
07/31/2024 19:33:54

Citigroup analyst David Lebowitz maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $80 to $88.

after-reporting-five-patient-deaths-data-committee-recommends-macrogenics-halt-prostate-cancer-trial
After Reporting Five Patient Deaths, Data ...
07/31/2024 17:45:20

MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 202...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION